[go: up one dir, main page]

UY30419A1 - Nuevos benzoxazoles heteroaril sustituidos - Google Patents

Nuevos benzoxazoles heteroaril sustituidos

Info

Publication number
UY30419A1
UY30419A1 UY30419A UY30419A UY30419A1 UY 30419 A1 UY30419 A1 UY 30419A1 UY 30419 A UY30419 A UY 30419A UY 30419 A UY30419 A UY 30419A UY 30419 A1 UY30419 A1 UY 30419A1
Authority
UY
Uruguay
Prior art keywords
substituted
heteroaril
alzheimer
disease
compositions
Prior art date
Application number
UY30419A
Other languages
English (en)
Inventor
Can Slivo
David Pyring
Sohn Daniel
Wensbo David-Edwards
Britt-Marie Swahn
Malmstrom Jonas
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=38833677&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=UY30419(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Publication of UY30419A1 publication Critical patent/UY30419A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Psychiatry (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

Derivados de benzoxazol heteroaril sustituidos, y sus usos terapéuticos, que tienen la formula estructural (Ia) y a su sal farmacéuticamente aceptable, composiciones y aplicaciones. Derivados de benzoxazol heteroaril sustituidos novedosos adecuados para la formacion de imágenes de depositos amiloide en pacientes vivos, sus composiciones, métodos de uso y procesos para fabricar dichos compuestos. Método para la formacion de imágenes de depositos amiloide en el cerebro in vivo de modo de permitir el diagnostico ante-mortem de mal de Alzheimer así como también para medir la eficacia clínica de los agentes terapéuticos para el mal de Alzheimer.
UY30419A 2006-06-19 2007-06-18 Nuevos benzoxazoles heteroaril sustituidos UY30419A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US81493606P 2006-06-19 2006-06-19

Publications (1)

Publication Number Publication Date
UY30419A1 true UY30419A1 (es) 2008-01-31

Family

ID=38833677

Family Applications (1)

Application Number Title Priority Date Filing Date
UY30419A UY30419A1 (es) 2006-06-19 2007-06-18 Nuevos benzoxazoles heteroaril sustituidos

Country Status (16)

Country Link
US (1) US7670591B2 (es)
EP (1) EP2035418A1 (es)
JP (1) JP5548842B2 (es)
KR (1) KR20090021224A (es)
CN (1) CN101506201B (es)
AR (1) AR061515A1 (es)
AU (1) AU2007261786A1 (es)
CA (1) CA2655084A1 (es)
CL (1) CL2007001784A1 (es)
IL (1) IL195669A0 (es)
MX (1) MX2008015718A (es)
NO (1) NO20090201L (es)
TW (1) TW200813035A (es)
UY (1) UY30419A1 (es)
WO (1) WO2007149030A1 (es)
ZA (1) ZA200810163B (es)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW200736252A (en) * 2006-01-27 2007-10-01 Astrazeneca Ab Novel heteroaryl substituted benzothiazoles
TW200901998A (en) 2007-03-06 2009-01-16 Astrazeneca Ab Novel 2-heteroaryl substituted benzothiophenes and benzofuranes
CA2725940A1 (en) * 2008-05-30 2009-12-23 Merck Sharp & Dohme Corp. Novel substituted azabenzoxazoles
JP2012507534A (ja) * 2008-10-31 2012-03-29 メルク・シャープ・エンド・ドーム・コーポレイション 新規置換アザベンゾオキサゾール類
US8779149B2 (en) * 2010-08-23 2014-07-15 Syntrix Biosystems, Inc. Aminopyridine- and aminopyrimidinecarboxamides as CXCR2 modulators
JP5937102B2 (ja) * 2010-12-14 2016-06-22 エレクトロフォレティクス リミテッド カゼインキナーゼ１デルタ（ｃｋ１デルタ）阻害剤
JPWO2014132919A1 (ja) * 2013-02-28 2017-02-02 国立大学法人京都大学 診断用組成物
KR101499329B1 (ko) * 2013-06-17 2015-03-06 주식회사 대웅제약 (2-(3,4-다이메톡시페닐)-5-(3-메톡시프로필)벤조퓨란)의결정형 및 이의 제조방법
JP6149684B2 (ja) * 2013-10-21 2017-06-21 ブラザー工業株式会社 携帯端末、画像処理装置、及びプログラム
CN106068619B (zh) * 2014-01-24 2019-11-19 华为技术有限公司 用于进行交叉极化干扰抑制的方法和设备
CN104059028B (zh) * 2014-06-06 2020-10-16 北京智博高科生物技术有限公司 与Aβ斑块具有亲和力的含手性侧链取代的氟代2-芳基苯并杂环化合物、其制备方法及应用
KR101709731B1 (ko) * 2015-05-22 2017-02-23 한국과학기술연구원 벤조옥사졸 또는 벤조티아졸 화합물, 그의 제조, 및 용도
US10324943B2 (en) * 2015-08-10 2019-06-18 Business Objects Software, Ltd. Auto-monitoring and adjustment of dynamic data visualizations
WO2017031239A1 (en) * 2015-08-18 2017-02-23 The Regents Of The University Of California Nitroxide containing amyloid binding agents for imaging and therapeutic uses
KR101812424B1 (ko) * 2016-12-28 2017-12-27 충북대학교 산학협력단 2-(2-아미노-5-(1-(피퍼리딘-4-일)-1H-피라졸-3-일)피리딘-3-일)벤조[d]옥사졸-6-올 및 이를 유효성분으로 포함하는 치매의 예방 및 치료용 조성물
WO2021154842A1 (en) * 2020-01-28 2021-08-05 Protego Biopharma, Inc. Compounds, compositions and methods for stabilizing transthyretin and inhibiting transthyretin misfolding

Family Cites Families (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU523040B2 (en) * 1978-05-15 1982-07-08 Kanebo Limited Calcium -antagonistic composition
GB8305245D0 (en) 1983-02-25 1983-03-30 Fujisawa Pharmaceutical Co Imidazo-heterocyclic compounds
JPS6394248A (ja) * 1986-10-08 1988-04-25 Canon Inc 電子写真感光体
CA2034309C (en) * 1990-01-22 1997-04-01 Takashi Iwaki Mesomorphic compound, liquid crystal composition containing same, liquid crystal device using same and display apparatus
AU1440395A (en) 1993-12-21 1995-07-10 Eli Lilly And Company Methods for the treatment or prevention of conditions associated with amyloidogenic reptides
US5518713A (en) * 1995-02-13 1996-05-21 3V Inc. Benzoxazole derivatives, the use thereof as sunscreens and cosmetic compositions containing them
JPH11116476A (ja) 1997-10-16 1999-04-27 Sankyo Co Ltd 縮合複素環化合物
DK2264018T3 (en) 2000-08-24 2015-05-11 Univ Pittsburgh Thioflavin derivatives for use in diagnosis of Alzheimer's disease
JP2004524289A (ja) 2000-12-22 2004-08-12 アストラゼネカ・アクチエボラーグ 治療化合物
US6596731B2 (en) 2001-03-27 2003-07-22 Hoffmann-La Roche Inc. Substituted imidazo[1,2-A] pyridine derivatives
CA2444214A1 (en) 2001-04-23 2002-10-31 The Trustees Of The University Of Pennsylvania Amyloid plaque aggregation inhibitors and diagnostic imaging agents
US7622479B2 (en) * 2001-11-26 2009-11-24 Takeda Pharmaceutical Company Limited Bicyclic derivative, its production and use
GB0130305D0 (en) 2001-12-19 2002-02-06 Amersham Plc Compounds for imaging alzheimers disease
WO2003106439A1 (ja) 2002-06-12 2003-12-24 株式会社ビーエフ研究所 アミロイド蓄積性疾患の画像診断プローブ化合物、老人斑／びまん性老人斑染色用化合物、ならびにアミロイド蓄積性疾患の治療薬
TW200401194A (en) 2002-07-11 2004-01-16 Advanced Micro Devices Inc Method and apparatus for determining a processor state without interrupting processor operation
AU2003258022A1 (en) 2002-08-02 2004-02-23 Genesoft Pharmaceuticals, Inc. Biaryl compounds having anti-infective activity
JP2004250411A (ja) 2003-02-21 2004-09-09 Bf Kenkyusho:Kk アミロイドβ蓄積性疾患の診断プローブおよび治療用化合物
CA2438032C (en) 2003-03-14 2013-05-07 University Of Pittsburgh Benzothiazole derivative compounds, compositions and uses
JPWO2004087641A1 (ja) 2003-03-31 2006-06-29 第一製薬株式会社 ヒドラゾン誘導体
JP4408291B2 (ja) 2003-05-13 2010-02-03 エフ．ホフマン−ラ ロシュ アーゲー アデノシン受容体リガンドとしての２−イミダゾ−ベンゾチアゾール
AU2005270026A1 (en) 2004-07-02 2006-02-09 University Of Pittsburgh - Of The Commonwealth System Of Higher Education Use of thioflavin radiolabeled derivatives in amyloid imaging for assessing anti-amyloid therapies
GB0420722D0 (en) 2004-09-17 2004-10-20 Addex Pharmaceuticals Sa Novel allosteric modulators
EP1893576A4 (en) 2005-05-27 2010-03-17 Univ Kingston TREATMENT OF PROTEIN DISORDERING
US20080219922A1 (en) 2005-09-12 2008-09-11 Goodman Mark M Alzheimer's Disease Imaging Agents
EP1937260A2 (en) 2005-09-16 2008-07-02 University of Pittsburgh In-vivo and in-vitro method for detecting amyloid deposits having at least one amyloidogenic protein
PT1945622E (pt) 2005-10-11 2012-04-09 Univ Pittsburgh Compostos de benzofurano marcados isotopicamente enquanto agentes de imagiologia para proteínas amilóides
EP1956013B1 (en) 2005-11-30 2016-04-13 Fujifilm RI Pharma Co., Ltd. Diagnostic and remedy for disease caused by amyloid aggregation and/or deposition
TW200736252A (en) 2006-01-27 2007-10-01 Astrazeneca Ab Novel heteroaryl substituted benzothiazoles
JP5376956B2 (ja) * 2006-02-10 2013-12-25 スムミト コーポレーション ピーエルシー デュシェンヌ型筋ジストロフィーの治療
EP2023919A4 (en) * 2006-05-08 2010-12-22 Molecular Neuroimaging Llc COMPOUNDS AND AMYLOID PROBES FOR THERAPY AND IMAGING USES
RU2009124537A (ru) 2007-01-22 2011-02-27 Астразенека Аб (Se) НОВЫЕ ГЕТЕРОАРИЛЗАМЕЩЕННЫЕ ПРОИЗВОДНЫЕ ИМИДАЗО(1,2-a)ПИРИДИНОВ

Also Published As

Publication number Publication date
WO2007149030A1 (en) 2007-12-27
EP2035418A1 (en) 2009-03-18
CN101506201B (zh) 2012-03-14
US7670591B2 (en) 2010-03-02
CN101506201A (zh) 2009-08-12
CL2007001784A1 (es) 2008-01-18
WO2007149030A8 (en) 2008-02-28
TW200813035A (en) 2008-03-16
NO20090201L (no) 2009-01-13
CA2655084A1 (en) 2007-12-27
JP2009541309A (ja) 2009-11-26
AU2007261786A1 (en) 2007-12-27
KR20090021224A (ko) 2009-02-27
IL195669A0 (en) 2009-09-01
MX2008015718A (es) 2008-12-19
AR061515A1 (es) 2008-09-03
US20080027051A1 (en) 2008-01-31
JP5548842B2 (ja) 2014-07-16
ZA200810163B (en) 2010-05-26

Similar Documents

Publication Publication Date Title
UY30419A1 (es) Nuevos benzoxazoles heteroaril sustituidos
ECSP088645A (es) Nuevos benzotiazoles sustituidos con heteroaril
WO2009155017A3 (en) Novel substituted azabenzoxazoles
MX375282B (es) Pirrolo[2,3-c]piridinas como agentes de formacion de imagenes para ovillos neurofibrilares.
MX2009007487A (es) Derivados de imidazo[1,2-a]piridina substituidos de heteroarilo novedosos.
UY30951A1 (es) Benzofuranos y benzotiofenos 2-heteroaril sustituidos novedosos 709
CL2012000708A1 (es) Compuestos derivados de imidazopiridina o imidazopirimidina, inhibidores de pde10a; proceso de preparacion de dichos compuestos; composiciones farmaceuticas; y su uso para el tratamiento terapeutico y/o preventivo de trastornos psicoticos, esquizofrenia, enfermedad de alzheimer, tumores solidos, entre otras enfermedades.
EA201101243A1 (ru) 3h-имидазо[4,5-c]пиридин-6-карбоксамиды в качестве противовоспалительных средств
EP2166854A4 (en) TRIAZONE DERIVATIVES FOR THE TREATMENT OF MORBUS ALZHEIMER AND RELATED SUFFERINGS
SV2011003939A (es) Piridiloxi-indoles inhibidores del vegf-r2 y uso de los mismos para el tratamiento de enfermedades
BRPI0515175A (pt) método para radiofluoração, composto, composição radiofarmacêutica, uso de um conjugado radiorrotulado ou um sal do mesmo, método para diagnose ou formação de imagem in vivo de uma doença ou condição associada com a angiogênese, e, método para monitorar o efeito do tratamento de um corpo humano ou animal com um medicamento para combater uma condição associada com cáncer
EP2135613A4 (en) MEDICAMENT AND DIAGNOSIS FOR BRAIN DISEASE DUE TO MITOCHONDRIAL DYSFUNCTION
AR114029A2 (es) Compuestos adecuados como precursores de compuestos que son útiles para obtener imágenes de depósitos amiloides, usos y procesos
EP2198292A4 (en) IMPROVED MORBUS ALZHEIMER DIAGNOSIS
EP2001503A4 (en) DIAGNOSIS AND TREATMENT OF MORBUS ALZHEIMER
BRPI1014595A2 (pt) procedimento de obtenção de novos derivados naftaleno para o diagnóstico in vivo de doença de alzheimer
EP2365974A4 (en) FLUORATED BENZOTHIAZOL DERIVATIVES, METHOD FOR THE PRODUCTION THEREOF AND IMAGE-DISPLAYING AGENT FOR THE DIAGNOSIS OF ALZHEIMER DISEASE, WHICH USES THEREOF
UY32829A (es) Derivados de 3-heteroaril-metil-imidazo-[1,2-b]-pirididazin - 6 -ilo
WO2010051196A8 (en) Novel substituted azabenzoxazoles
RU2007118691A (ru) Применение 4-трифторметилфениламида (z)-2-циано-3-гидрокси-бут-2-еновой кислоты для лечения воспалительных заболеваний кишечника
BRPI0808090A2 (pt) Composto, composição farmacêutica, e, método in vivo para medir depósitos de amilóide em um paciente
EP2117309A4 (en) BICYCLIC SPIROPIPERIDINE BETA SEKRETASE INHIBITORS FOR THE TREATMENT OF ALZHEIMER DISEASE
ECSP099082A (es) Beta-agonistas enantioméricamente puros, procedimientos para su preparación y su uso como medicamentos
HN2009003463A (es) Derivados de n5-(2-etoxi-etil)-n3-(2- piridinil) -3,5- piperidin-dicarboxamida para usarse como inhibidores de renina
MX2025010406A (es) Aglutinantes de alfa-sinucleina y metodos de uso

Legal Events

Date Code Title Description
109 Application deemed to be withdrawn

Effective date: 20170711